Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Neoantigen specific TCR-T cell drug product
BIOLOGICAL
2 trials
Sponsors
Alaunos Therapeutics
Conditions
Adenocarcinoma of Lung
Adenosquamous Cell Lung Cancer
Cholangiocarcinoma
Colorectal Cancer
Endometrial Cancer
Gynecologic Cancer
Non-small Cell Lung Cancer
Ovarian Cancer
+4 more
Phase 1
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Terminated
NCT05194735
Alaunos Therapeutics
Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer, Cholangiocarcinoma +9
Start: 2022-04-04
End: 2023-08-14
Updated: 2025-11-07
Unknown Phase
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Completed
NCT05292859
Alaunos Therapeutics
Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer, Cholangiocarcinoma +7
Start: 2023-03-01
End: 2025-05-30
Updated: 2025-07-30
Related Papers
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.
Journal of Clinical Oncology
2023-06-01
8 citations
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
Journal of Clinical Oncology
2022-06-01
2 citations